AXGN

Based on AxoGen, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does AxoGen do?

AxoGen develops and sells surgical products for peripheral nerve repair. Its portfolio includes processed human nerve allografts and porcine-derived tissue products that surgeons use to bridge, protect, and reconstruct damaged nerves — without requiring a second surgical harvest site from the patient.

Does AXGN pay dividends?

No, AxoGen does not currently pay a dividend. The company is in a growth phase and retains capital to fund commercial expansion and product development rather than returning cash to shareholders through distributions.

When does AXGN report earnings?

AxoGen reports financial results on a quarterly basis, in line with standard US-listed company practice. For exact dates and the most recent results, check AxoGen's investor relations page, as our data source does not cover specific upcoming earnings dates.

Is AXGN a good stock to buy?

UQS Score rates AXGN as Below Average overall. The Growth and Risk pillars show relative strength, but Weak Quality and Moat ratings highlight real challenges. Whether it fits your portfolio depends on your risk tolerance and investment thesis — view the full pillar breakdown on UQS Pro.

Is AXGN overvalued?

The UQS Valuation pillar for AXGN is rated Neutral, suggesting the current market price reflects a balanced — neither clearly cheap nor obviously expensive — view of the company's growth prospects relative to its fundamentals.

How does AXGN compare to its competitors?

AxoGen occupies a highly specialized niche in peripheral nerve repair biologics. Peers like Artivion operate in adjacent tissue-processing markets, while Establishment Labs and AdaptHealth address different surgical and healthcare service segments. UQS Pro shows side-by-side pillar comparisons for a deeper view.

What is AXGN's market cap bracket?

AxoGen is classified as a mid-cap company. This places it in a bracket that typically offers more growth optionality than large-caps but with greater volatility and liquidity considerations than mega-cap healthcare names.

Who founded AxoGen?

AxoGen traces its origins to 1986. Detailed founding history, including original founders, is publicly available through the company's official corporate history and SEC filings on its investor relations site.

Is AXGN a long-term quality indicator?

As a long-term quality indicator, AXGN's UQS profile is mixed. The Good Growth rating suggests commercial momentum, but Weak Quality and Moat scores indicate the company has not yet demonstrated the durable competitive advantages and consistent profitability that typically characterize high-quality long-term holdings.

What is the main competitive advantage of AxoGen?

AxoGen's primary competitive position comes from its specialized focus on peripheral nerve repair and its portfolio of off-the-shelf biological products. However, the UQS Moat pillar rates this advantage as Weak, suggesting the company faces meaningful competition and has limited pricing power relative to stronger-moat peers.

What sector does AXGN belong to?

AxoGen operates in the Healthcare sector, specifically within the medical devices and biologics subsegment. It focuses on a narrow but clinically important area — surgical solutions for peripheral nerve damage — serving plastic, orthopedic, hand, and oral surgeons.

Is AXGN a growth stock or value stock?

Based on its UQS profile, AXGN leans toward the growth category — the Growth pillar earns a Good rating while Valuation is Neutral. It is not a deep-value play, nor does it carry the premium valuation of a high-conviction growth stock. It sits in an in-between zone.

AxoGen, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

AxoGen, Inc. demonstrates healthy growth trends across revenue and earnings.

AxoGen, Inc. carries minimal financial risk with conservative leverage and strong solvency.

AxoGen, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.

AxoGen, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AXGN.

The UQS (Unified Quality Score) for AxoGen, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses AxoGen, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether AxoGen, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.